Interventional CT represents a strategic opportunity for Medrad. The company has signed its second distribution agreement in three months, this one with Lakewood, CO-based UltraGuide, for products addressing this market segment.Medrad, a U.S. subsidiary
Interventional CT represents a strategic opportunity for Medrad. The company has signed its second distribution agreement in three months, this one with Lakewood, CO-based UltraGuide, for products addressing this market segment.
Medrad, a U.S. subsidiary of Schering, agreed in January to begin distributing UltraGuide's CT-Guide in the U.S. and France. The visual guidance system designed for minimally invasive CT procedures will be marketed along with SimpliCT, a CT guidance device manufactured by NeoRad. A distribution agreement for SimpliCT was signed in November. Interventional guidance is a natural extension of Medrad's product lines, according to the company, which provides MRI surface coils and power injectors for contrast-enhanced studies.
Mammography Study Compares False Positives Between AI and Radiologists in DBT Screening
May 8th 2025For DBT breast cancer screening, 47 percent of radiologist-only flagged false positives involved mass presentations whereas 40 percent of AI-only flagged false positive cases involved benign calcifications, according to research presented at the recent American Roentgen Ray Society (ARRS) conference.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.